Search

Author/Creator Riddle, Evan

1. 071 Natalizumab extended interval dosing (EID) is associated with a significant reduction in progressive multifocal leukoencephalopathy (PML) risk compared with standard interval dosing (SID) in the touch® prescribing program. Issue 6 (24th May 2018)

Authors:
Ryerson, Lana Zhovtis; Foley, John; Chang, Ih; Kister, Ilya; Cutter, Gary; Metzger, Ryan; Goldberg, Judith D; Li, Xiaochun; Riddle, Evan; Smirnakis, Karen; Yu, Bei; Ren, Zheng; Hotermans, Christophe; Ho, Pei-Ran; Campbell, Nolan
Journal:
Journal of neurology, neurosurgery and psychiatry
Issue:
Volume 89:Issue 6(2018)
Page Start:
A29
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. (8th October 2019)

Authors:
Ryerson, Lana Zhovtis; Foley, John; Chang, Ih; Kister, Ilya; Cutter, Gary; Metzger, Ryan R.; Goldberg, Judith D.; Li, Xiaochun; Riddle, Evan; Smirnakis, Karen; Kasliwal, Rachna; Ren, Zheng; Hotermans, Christophe; Ho, Pei-Ran; Campbell, Nolan
Journal:
Neurology
Issue:
Volume 93:Number 15(2019)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Serum neurofilament light levels in natalizumab-treated patients with multiple sclerosis who switch to extended interval dosing from every-4-week dosing in real-world clinical practice. (February 2023)

Authors:
Foley, John; Xiong, Kuangnan; Hoyt, Tammy; Singh, Carol M; Riddle, Evan; de Moor, Carl; Plavina, Tatiana; Campbell, Nolan
Journal:
Multiple sclerosis
Issue:
Volume 29:Number 2(2023)
Page Start:
196
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗